Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;42(6):699-709.
doi: 10.1007/s00774-024-01542-2. Epub 2024 Aug 13.

Effect of bisphosphonate and denosumab treatment on TBS in Japanese breast cancer patients with AIBL

Emi Onuma  1 , Shin Saito  2 , Taku Tsuburai  1 , Hiromi Yoshikata  1 , Shoko Adachi  3 , Shinya Yamamoto  3 , Kazutaka Narui  3 , Tomonari Hayama  1   4 , Mariko Murase  4 , Taichi Mizushima  5 , Etsuko Miyagi  5 , Hideya Sakakibara  1 , Ryoko Asano  1
Affiliations

Effect of bisphosphonate and denosumab treatment on TBS in Japanese breast cancer patients with AIBL

Emi Onuma et al. J Bone Miner Metab. 2024 Nov.

Abstract

Introduction: Bisphosphonates and denosumab increase bone mineral density (BMD) for osteoporosis treatment in patients with aromatase inhibitor-associated bone loss (AIBL). This study aimed to directly compare bisphosphonates with denosumab in treating patients with AIBL and to determine the effect of denosumab on the trabecular bone score (TBS).

Materials and methods: Thirty-nine patients with AIBL receiving osteoporosis treatment (21 in the bisphosphonates group and 18 in the denosumab group) were retrospectively evaluated for changes in lumbar spine and femoral BMD, lumbar spine bone quality (assessed by TBS), and blood bone metabolic markers. The Mann-Whitney and Wilcoxon tests were used for statistical evaluation.

Results: After 24 months of treatment, the lumbar spine BMD change rate was 5.82 ± 1.10% with bisphosphonates and 10.49 ± 1.20% with denosumab, with the change rate of denosumab significantly increasing over that of bisphosphonates. The change rate in femoral BMD was 2.69 ± 1.16% with bisphosphonates and 2.95 ± 1.26% with denosumab, with no significant difference between the two groups. The rate of decrease in tartrate-resistant acid phosphatase isoform 5b was significantly higher in the denosumab group. The change rate in TBS at 24 months of treatment was 0.53 ± 1.26% in the bisphosphonates group and 1.08 ± 1.33% in the denosumab group, with no significant difference between the two groups. After 24 months, TBS remained stable.

Conclusion: Both bisphosphonates and denosumab may increase BMD, improve bone metabolism, and inhibit bone quality loss in patients with AIBL.

Keywords: Aromatase inhibitor; Bisphosphonates; Breast cancer; Denosumab; Trabecular bone score.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: None of the authors have any potential conflict of interest associated with this work.

References

    1. National Comprehensive Cancer Network clinical practice guidelines in oncology (2023) Breast Cancer. Version 4. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
    1. Chien AJ, Goss PE (2006) Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol 24:5305–5312 - PubMed - DOI
    1. Body JJ (2012) Aromatase inhibitors-induced bone loss in early breast cancer. Bon Key Rep 1:201 - DOI
    1. Waqas K, Ferreira JL, Tsourdi E, Body JJ, Hadji P, Zillikens MC (2021) Update guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer. J Bone Oncol 28:1–11 - DOI
    1. Fukumoto S, Soen S, Taguchi T, Ishikawa T, Matsushima H, Terauchi M, Horie S, Yoneda T, Sugimoto T, Matsumoto T (2020) Management manual for cancer treatment-induced bone loss (CTIBL): position statement of the JSBMR. J Bone Miner Metab 38:141–144 - PubMed - DOI

MeSH terms

LinkOut - more resources